Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8238248 | 0.84 | LTA4H (0.41) | LTA4H | |
| SCHEMBL30115266 | 0.84 | — | — | |
| SCHEMBL4845985 | 0.84 | — | — | |
| SCHEMBL63739 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL22692042 | 0.82 | LTA4H (0.41) | LTA4H | |
| Hydrochloric Acid SCHEMBL1204751 | 0.82 | LTA4H (0.41) | LTA4H | |
| SCHEMBL2911420 | 0.77 | CXCR4 (0.39) | LTA4H | |
| SCHEMBL2138694 | 0.72 | — | — | |
| SCHEMBL31495603 | 0.72 | — | — | |
| SCHEMBL2912288 | 0.71 | CHRNB4 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171198-A1 | SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease | METAPHORE PHARMACEUTICALS, INC. | 2005-08-04 | — | — | US | disclosed |
| US-20050171198-A1 | SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease | METAPHORE PHARMACEUTICALS, INC. | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171198-A1 | SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease | SOD1, MPO, SOD3 | LTA4H 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.